Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Morales Garcia, Jose A ^a   Redondo, Miriam ^b   Alonso Gil, Sandra ^a   Gil, Carmen ^b   Perez, Concepción ^b   Martinez, Ana ^b   Santos, Angel ^c   Perez Castillo, Ana ^a  

^a CSIC   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; LIPOPOLYSACCHARIDE; PHENYL 2 THIOXO (1H)QUINAZOLIN 4 ONE; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VII INHIBITOR; S 14; UNCLASSIFIED DRUG; DOPAMINE; NEUROPROTECTIVE AGENT; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICROGLIA; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; CELL PROTECTION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; RODENT; WISTAR RAT;

RATTUS; RODENTIA;

ANIMALS; CELLS, CULTURED; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MODELS, BIOLOGICAL; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; RODENTIA;

EID: 79952129158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017240     Document Type: Article

References (56)

1. Damier P, Hirsch EC, Agid Y, Graybiel AM, (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (Pt 8): 1437-1448.
2. Tansey MG, McCoy MK, Frank-Cannon TC, (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental neurology 208: 1-25.
3. McGeer EG, McGeer PL, (2007) The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 21: 789-797.
4. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM, (2005) A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 128: 2665-2674.
5. McGeer PL, Schwab C, Parent A, Doudet D, (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54: 599-604.
6. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, et al. (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15: 991-998.
7. Gagne JJ, Power MC, (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74: 995-1002.
8. Volakakis N, Kadkhodaei B, Joodmardi E, Wallis K, Panman L, et al. (2010) NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. Proc Natl Acad Sci U S A 107: 12317-12322.
9. Lonze BE, Ginty DD, (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35: 605-623.
10. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M, (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13: 29-35.
11. Conti M, Beavo J, (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
12. Bender AT, Beavo JA, (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
13. Kleppisch T, (2009) Phosphodiesterases in the central nervous system. Handb Exp Pharmacol pp. 71-92.
14. Giembycz MA, Smith SJ, (2006) Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12: 3207-3220.
15. Miro X, Perez-Torres S, Palacios JM, Puigdomenech P, Mengod G, (2001) Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 40: 201-214.
16. Sasaki T, Kotera J, Omori K, (2002) Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 361: 211-220.
17. Reyes-Irisarri E, Perez-Torres S, Mengod G, (2005) Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 132: 1173-1185.
18. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, et al. (2002) Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128: 460-466.
19. Gil C, Campillo N, Perez A, Martinez A, (2008) Phosphodiesteresae 7 (PDE7) inhibitors as new drugs for neurological and anti-inflammatory disorders. ExpOpinTherPatents 18: 1127-1139.
20. Martinez A, Castro A, Gil C, Miralpeix M, Segarra V, et al. (2000) Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem 43: 683-689.
21. Castro A, Jerez MJ, Gil C, Martinez A, (2005) Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 25: 229-244.
22. Castro A, Jerez MJ, Gil C, Calderon F, Domenech T, et al. (2008) CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem 43: 1349-1359.
23. Castano T, Wang H, Campillo NE, Ballester S, Gonzalez-Garcia C, et al. (2009) Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem 4: 866-876.
24. Takahashi T, Deng Y, Maruyama W, Dostert P, Kawai M, et al. (1994) Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J Neural Transm Gen Sect 98: 107-118.
25. Houslay MD, Kolch W, (2000) Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58: 659-668.
26. Charles MP, Adamski D, Kholler B, Pelletier L, Berger F, et al. (2003) Induction of neurite outgrowth in PC12 cells by the bacterial nucleoside N6-methyldeoxyadenosine is mediated through adenosine A2a receptors and via cAMP and MAPK signaling pathways. Biochem Biophys Res Commun 304: 795-800.
27. Lastres-Becker I, Fernandez-Perez A, Cebolla B, Vallejo M, (2008) Pituitary adenylate cyclase-activating polypeptide stimulates glial fibrillary acidic protein gene expression in cortical precursor cells by activating Ras and Rap1. Mol Cell Neurosci 39: 291-301.
28. Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, et al. (2008) Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation. Neurosci Lett 448: 175-179.
29. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, et al. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20: 6309-6316.
30. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, et al. (2006) Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26: 9365-9375.
31. Ouyang M, Shen X, (2006) Critical role of ASK1 in the 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J Neurochem 97: 234-244.
32. Bos JL, (2003) Epac: a new cAMP target and new avenues in cAMP research. Nat Rev Mol Cell Biol 4: 733-738.
33. Pham N, Cheglakov I, Koch CA, de Hoog CL, Moran MF, et al. (2000) The guanine nucleotide exchange factor CNrasGEF activates ras in response to cAMP and cGMP. Current biology 10: 555-558.
34. Stetler RA, Gao Y, Zukin RS, Vosler PS, Zhang L, et al. Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. Proc Natl Acad Sci U S A 107: 3204-3209.
35. Lee B, Butcher GQ, Hoyt KR, Impey S, Obrietan K, (2005) Activity-dependent neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB phosphorylation at serine 133. J Neurosci 25: 1137-1148.
36. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, et al. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 31: 47-54.
37. Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291: 2423-2428.
38. Jiang H, Nucifora FC Jr, Ross CA, DeFranco DB, (2003) Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum Mol Genet 12: 1-12.
39. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, et al. (2000) Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet 26: 29-36.
40. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
41. Townsend KP, Pratico D, (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. Faseb J 19: 1592-1601.
42. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, et al. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064.
43. Hald A, Lotharius J, (2005) Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 193: 279-290.
44. Liu B, Du L, Hong JS, (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293: 607-617.
45. Dutta G, Zhang P, Liu B, (2008) The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22: 453-464.
46. Anden NE, Dahlstrom A, Fuxe K, Larsson K, (1966) Functional role of the nigro-neostriatal dopamine neurons. Acta Pharmacol Toxicol (Copenh) 24: 263-274.
47. Ungerstedt U, Arbuthnott GW, (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
48. Schwarting RK, Huston JP, (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331.
49. Toledo-Aral JJ, Mendez-Ferrer S, Pardal R, Lopez-Barneo J, (2002) Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease. Brain Res Bull 57: 847-853.
50. Paxinos GaW, C, (1998) The Rat Brain in Stereotaxic Coordinates. San-Diego Academic Press.
51. Heneka MT, Klockgether T, Feinstein DL, (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20: 6862-6867.
52. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, et al. (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. The Journal of neuroscience 27: 5766-5776.
53. Morales-Garcia JA, Luna-Medina R, Martinez A, Santos A, Perez-Castillo A, (2009) Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. J Neurosci Res 87: 3687-3696.
54. Cortes-Canteli M, Luna-Medina R, Sanz-Sancristobal M, Alvarez-Barrientos A, Santos A, et al. (2008) CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury. J Cell Sci 121: 1224-1234.
55. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, et al. (2005) Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor {gamma} Activation. J Biol Chem 280: 21453-21462.
56. Cortes-Canteli M, Wagner M, Ansorge W, Perez-Castillo A, (2004) Microarray analysis supports a role for ccaat/enhancer-binding protein-beta in brain injury. J Biol Chem 279: 14409-14417.